BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 32138690)

  • 1. Silencing of microRNA-210 inhibits the progression of liver cancer and hepatitis B virus-associated liver cancer via targeting EGR3.
    Li X; Yuan M; Song L; Wang Y
    BMC Med Genet; 2020 Mar; 21(1):48. PubMed ID: 32138690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MiR-19a, miR-122 and miR-223 are differentially regulated by hepatitis B virus X protein and involve in cell proliferation in hepatoma cells.
    Yu G; Chen X; Chen S; Ye W; Hou K; Liang M
    J Transl Med; 2016 May; 14(1):122. PubMed ID: 27150195
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MicroRNA-98-5p Inhibits Tumorigenesis of Hepatitis B Virus-Related Hepatocellular Carcinoma by Targeting NF-κB-Inducing Kinase.
    Fei X; Zhang P; Pan Y; Liu Y
    Yonsei Med J; 2020 Jun; 61(6):460-470. PubMed ID: 32469170
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long non-coding RNA F11-AS1 inhibits HBV-related hepatocellular carcinoma progression by regulating NR1I3 via binding to microRNA-211-5p.
    Deng Y; Wei Z; Huang M; Xu G; Wei W; Peng B; Nong S; Qin H
    J Cell Mol Med; 2020 Jan; 24(2):1848-1865. PubMed ID: 31880390
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MiR-222-3p induced by hepatitis B virus promotes the proliferation and inhibits apoptosis in hepatocellular carcinoma by upregulating THBS1.
    Sun Y; Shi P; Wu Q; Liu B; Yu Z; Jia H; Chang H
    Hum Cell; 2021 Nov; 34(6):1788-1799. PubMed ID: 34273068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatitis B Virus-Encoded MicroRNA (HBV-miR-3) Regulates Host Gene PPM1A Related to Hepatocellular Carcinoma.
    Chavalit T; Nimsamer P; Sirivassanametha K; Anuntakarun S; Saengchoowong S; Tangkijvanich P; Payungporn S
    Microrna; 2020; 9(3):232-239. PubMed ID: 31686644
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MicroRNA-325-3p inhibits cell proliferation and induces apoptosis in hepatitis B virus-related hepatocellular carcinoma by down-regulation of aquaporin 5.
    Zhang Z; Han Y; Sun G; Liu X; Jia X; Yu X
    Cell Mol Biol Lett; 2019; 24():13. PubMed ID: 30805015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Downregulation of MicroRNA-145 Caused by Hepatitis B Virus X Protein Promotes Expression of CUL5 and Contributes to Pathogenesis of Hepatitis B Virus-Associated Hepatocellular Carcinoma.
    Gao F; Sun X; Wang L; Tang S; Yan C
    Cell Physiol Biochem; 2015; 37(4):1547-59. PubMed ID: 26512974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Promoting effect of hepatitis B virus on the expressoin of phospholipase A2 group IIA.
    Zhu C; Song H; Shen B; Wu L; Liu F; Liu X
    Lipids Health Dis; 2017 Jan; 16(1):5. PubMed ID: 28077172
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor suppressor micro RNA miR-145 and onco micro RNAs miR-21 and miR-222 expressions are differentially modulated by hepatitis B virus X protein in malignant hepatocytes.
    Bandopadhyay M; Banerjee A; Sarkar N; Panigrahi R; Datta S; Pal A; Singh SP; Biswas A; Chakrabarti S; Chakravarty R
    BMC Cancer; 2014 Sep; 14():721. PubMed ID: 25260533
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of potential miRNA-mRNA regulatory network contributing to pathogenesis of HBV-related HCC.
    Lou W; Liu J; Ding B; Chen D; Xu L; Ding J; Jiang D; Zhou L; Zheng S; Fan W
    J Transl Med; 2019 Jan; 17(1):7. PubMed ID: 30602391
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatitis B virus X protein promotes human hepatoma cell growth via upregulation of transcription factor AP2α and sphingosine kinase 1.
    Lu ZP; Xiao ZL; Yang Z; Li J; Feng GX; Chen FQ; Li YH; Feng JY; Gao YE; Ye LH; Zhang XD
    Acta Pharmacol Sin; 2015 Oct; 36(10):1228-36. PubMed ID: 26073327
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MicroRNA‑1271‑5p alleviates the malignant development of hepatitis B virus‑mediated liver cancer via binding to AQP5.
    Li Z; Ma L; Di L; Lin X
    Mol Med Rep; 2021 May; 23(5):. PubMed ID: 33760167
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of miR-520e-mediated MAPK signalling pathway on HBV replication and regulation of hepatocellular carcinoma cells via targeting EphA2.
    Tian JH; Liu WD; Zhang ZY; Tang LH; Li D; Tian ZJ; Lin SW; Li YJ
    J Viral Hepat; 2019 Apr; 26(4):496-505. PubMed ID: 30521133
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DTNA promotes HBV-induced hepatocellular carcinoma progression by activating STAT3 and regulating TGFβ1 and P53 signaling.
    Hu ZG; Zhang S; Chen YB; Cao W; Zhou ZY; Zhang JN; Gao G; He SQ
    Life Sci; 2020 Oct; 258():118029. PubMed ID: 32619495
    [TBL] [Abstract][Full Text] [Related]  

  • 16. miR-106b promotes cancer progression in hepatitis B virus-associated hepatocellular carcinoma.
    Yen CS; Su ZR; Lee YP; Liu IT; Yen CJ
    World J Gastroenterol; 2016 Jun; 22(22):5183-92. PubMed ID: 27298561
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dynamic expression of ZNF382 and its tumor-suppressor role in hepatitis B virus-related hepatocellular carcinogenesis.
    Dang S; Zhou J; Chen Y; Chen P; Ji M; Shi B; Yang Q; Hou P
    Oncogene; 2019 Jun; 38(24):4804-4819. PubMed ID: 30804458
    [TBL] [Abstract][Full Text] [Related]  

  • 18. miR-122 inhibits viral replication and cell proliferation in hepatitis B virus-related hepatocellular carcinoma and targets NDRG3.
    Fan CG; Wang CM; Tian C; Wang Y; Li L; Sun WS; Li RF; Liu YG
    Oncol Rep; 2011 Nov; 26(5):1281-6. PubMed ID: 21725618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early growth response 3 inhibits growth of hepatocellular carcinoma cells via upregulation of Fas ligand.
    Zhang S; Xia C; Xu C; Liu J; Zhu H; Yang Y; Xu F; Zhao J; Chang Y; Zhao Q
    Int J Oncol; 2017 Mar; 50(3):805-814. PubMed ID: 28098878
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Upregulated in Hepatitis B virus-associated hepatocellular carcinoma cells, miR-331-3p promotes proliferation of hepatocellular carcinoma cells by targeting ING5.
    Cao Y; Chen J; Wang D; Peng H; Tan X; Xiong D; Huang A; Tang H
    Oncotarget; 2015 Nov; 6(35):38093-106. PubMed ID: 26497554
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.